Journal
MOVEMENT DISORDERS
Volume 19, Issue 10, Pages 1175-1182Publisher
WILEY
DOI: 10.1002/mds.20112
Keywords
parkinsonism; I-123-ioflupane; dopainine transporter
Categories
Ask authors/readers for more resources
Imaging with I-123-loflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis or presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of I-123-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. (C) 2004 Movement Disorder Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available